These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 23820653)
1. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3). Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653 [TBL] [Abstract][Full Text] [Related]
2. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin. Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence]. Janane A; Hajji F; Ismail TO; Elondo JC; Ghadouane M; Ameur A; Abbar M; Bouzidi A Actas Urol Esp; 2011 Apr; 35(4):189-94. PubMed ID: 21419519 [TBL] [Abstract][Full Text] [Related]
4. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection. Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082 [TBL] [Abstract][Full Text] [Related]
5. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer. Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769 [TBL] [Abstract][Full Text] [Related]
6. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323 [TBL] [Abstract][Full Text] [Related]
7. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529 [TBL] [Abstract][Full Text] [Related]
8. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. Dinney CP; Babkowski RC; Antelo M; Perrotte P; Liebert M; Zhang HZ; Palmer J; Veltri RW; Katz RL; Grossman HB J Urol; 1998 Oct; 160(4):1285-90. PubMed ID: 9751337 [TBL] [Abstract][Full Text] [Related]
9. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618 [TBL] [Abstract][Full Text] [Related]
10. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion]. Słojewski M Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306 [TBL] [Abstract][Full Text] [Related]
12. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418 [TBL] [Abstract][Full Text] [Related]
13. The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study. Shim JS; Choi H; Noh TI; Tae JH; Yoon SG; Kang SH; Bae JH; Park HS; Park JY Korean J Urol; 2015 Jun; 56(6):429-34. PubMed ID: 26078839 [TBL] [Abstract][Full Text] [Related]
14. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin. Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562 [TBL] [Abstract][Full Text] [Related]
15. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744 [TBL] [Abstract][Full Text] [Related]
16. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer. Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798 [TBL] [Abstract][Full Text] [Related]
17. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744 [TBL] [Abstract][Full Text] [Related]
18. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Younes M; Juarez D; Lechago LV; Lerner SP Anticancer Res; 2001; 21(1B):575-8. PubMed ID: 11299807 [TBL] [Abstract][Full Text] [Related]
19. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C; J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497 [TBL] [Abstract][Full Text] [Related]
20. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]